G1 Therapeutics Inc (NASDAQ:GTHX) Expected to Post Earnings of -$0.98 Per Share

Wall Street brokerages expect G1 Therapeutics Inc (NASDAQ:GTHX) to announce earnings per share of ($0.98) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for G1 Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.91) and the lowest estimate coming in at ($1.05). G1 Therapeutics posted earnings of ($0.64) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 53.1%. The firm is scheduled to issue its next earnings report on Thursday, May 14th.

On average, analysts expect that G1 Therapeutics will report full-year earnings of ($4.00) per share for the current fiscal year, with EPS estimates ranging from ($4.40) to ($3.55). For the next financial year, analysts anticipate that the business will post earnings of ($4.26) per share, with EPS estimates ranging from ($5.01) to ($3.84). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow G1 Therapeutics.

G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Wednesday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.02.

GTHX has been the topic of a number of research reports. BTIG Research raised their target price on shares of G1 Therapeutics from $51.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Wedbush lowered their price objective on shares of G1 Therapeutics from $67.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $82.00 price objective (up from $72.00) on shares of G1 Therapeutics in a research report on Tuesday, January 21st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $74.00 price objective on shares of G1 Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $59.71.

Shares of GTHX opened at $12.08 on Tuesday. The company has a current ratio of 13.71, a quick ratio of 13.71 and a debt-to-equity ratio of 0.04. The firm has a market cap of $420.46 million, a PE ratio of -3.71 and a beta of 2.11. The company’s 50 day simple moving average is $16.27 and its 200-day simple moving average is $23.18. G1 Therapeutics has a 12-month low of $8.80 and a 12-month high of $41.80.

A number of large investors have recently bought and sold shares of the stock. Franklin Street Advisors Inc. NC acquired a new stake in G1 Therapeutics in the fourth quarter valued at $211,000. Geode Capital Management LLC lifted its holdings in G1 Therapeutics by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 415,705 shares of the company’s stock valued at $10,987,000 after acquiring an additional 14,989 shares during the period. Tang Capital Management LLC lifted its holdings in G1 Therapeutics by 13.3% in the fourth quarter. Tang Capital Management LLC now owns 170,000 shares of the company’s stock valued at $4,493,000 after acquiring an additional 20,000 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in G1 Therapeutics in the fourth quarter valued at $311,000. Finally, UBS Asset Management Americas Inc. lifted its holdings in G1 Therapeutics by 3.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 252,236 shares of the company’s stock valued at $6,667,000 after acquiring an additional 7,840 shares during the period. Hedge funds and other institutional investors own 80.20% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Further Reading: How are Outstanding Shares Different from Authorized Shares?

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.